Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we?

Figure 2 A roadmap for the improvement of biomarker research in metabolic dysfunction-associated steatotic liver disease: Discovery of a biologically, and perhaps clinically, interesting omics-based biomarker; analytical, biological/clinical validation of the discovered biomarker; and finally, the evaluation for its clinical utility and use, and the evaluation for its economic benefits (cost-effectiveness or cost-utility studies). A summary of the criteria for the development path of omics-based predictors proposed by the United States National Cancer Institute are also included in the roadmap. Modified from freepik.com.